NCT06497543View on ClinicalTrials.gov

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

April 30, 2026

Conditions
Small-cell Lung Cancer
Interventions
DRUG

Intrathecal Pemetrexed

Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.

Trial Locations (1)

410013

Yongchang Zhang, Changsha

All Listed Sponsors
collaborator

Second People's Hospital of Hunan

OTHER

lead

Hunan Province Tumor Hospital

OTHER

NCT06497543 - Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic | Biotech Hunter | Biotech Hunter